Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Novartis announces approval of Extavia

Novartis announces approval of Extavia

17th August 2009

Novartis has revealed that its multiple sclerosis (MS) treatment Extavia has received approval from the Food and Drug Administration (FDA).

The therapy, which is the first of a series of medicines the firm is developing for the treatment and management of the disease, is the same medicinal product as Betaseron.

Extavia has been approved by the FDA to treat relapsing forms of MS and reduces the frequency of flare-ups in patients. It is also recommended for use by those experiencing a first clinical episode of the disease as revealed by magnetic resonance imaging.

Joe Jimenez, chief executive of the Novartis’ pharmaceuticals division, commented: “We are committed to providing new approaches to MS care, and the FDA approval of Extavia marks the beginning of our long-term commitment to the MS community in the US.”

Last week, Novartis revealed that it has completed orders for supplies of its seasonal flu vaccine and is in the process of shipping them to international organisations.

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.